RGA Funding Advisors, an funding administration firm, has launched its second-quarter 2025 investor letter. A duplicate of the letter will be downloaded right here. The second quarter-end figures hid the inherent volatility available in the market, which started with a steep sell-off and ended with readability round international commerce that modified the atmosphere for evaluating enterprises. As well as, you possibly can test the fund’s high 5 holdings to find out its greatest picks for 2025.
In its second-quarter 2025 investor letter, RGA Funding Advisors highlighted shares corresponding to CRISPR Therapeutics AG (NASDAQ:CRSP). CRISPR Therapeutics AG (NASDAQ:CRSP) is a gene enhancing firm. The one-month return of CRISPR Therapeutics AG (NASDAQ:CRSP) was -8.57%, and its shares gained 19.87% of their worth over the past 52 weeks. On August 15, 2025, CRISPR Therapeutics AG (NASDAQ:CRSP) inventory closed at $59.73 per share, with a market capitalization of $5.432 billion.
RGA Funding Advisors said the next concerning CRISPR Therapeutics AG (NASDAQ:CRSP) in its second quarter 2025 investor letter:
“After industrial approval of Casgevy, CRISPR Therapeutics AG (NASDAQ:CRSP) shares traded over $90. At their worst within the April crash, shares modified palms at $30, a 2/third low cost to their post-approval peak. The commerce warfare would finally have a negligible impression on CRSP, however shares dropped almost 30% within the Spring collapse. This made little sense to us, particularly given the substantial money stability the corporate has constructed with prudent financings alongside the best way.
